
Aptevo Therapeutics Inc.
$4.82
-0.0450 (-0.93%)
Latest News
Aptevo to Participate in March 2026 Conferences
Mar 19, 2026 08:05 AM
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Mar 10, 2026 08:05 AM
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Feb 03, 2026 08:05 AM
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Jan 09, 2026 08:05 AM
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Dec 26, 2025 08:05 AM
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Dec 09, 2025 08:05 AM
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Nov 10, 2025 08:05 AM
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Nov 06, 2025 08:05 AM
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
Oct 08, 2025 08:20 AM
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Sep 16, 2025 08:30 AM
Sign Up For APVO Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Aptevo Therapeutics (APVO) is a client of RedChip Companies. APVO agreed to pay RedChip Companies, Inc. a $9,000 monthly cash fee, beginning May 2025, for 6 months of investor awareness services. APVO also agreed to pay RedChip a one-time $50,000 cash fee for a 10-day national TV ad campaign aired November 18 to November 29, 2024, a one-time $45,000 cash fee for a 10-day national TV ad campaign aired December 4 to December 17, 2024, a one-time $45,000 cash fee for a 10-day national TV ad campaign aired February 17 to February 28, 2025, and a one-time $75,000 cash fee for a four-week national TV ad campaign aired in May 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.